Carden

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Carden

Property Description
Active ingredient Atenolol
Form Oral tablet
Pharmacological class beta1-Selective Beta-Blocker
Common use Circulatory stability and pressure control
Origin Synthetic
Prescription Status Prescription-only medicine (Rx)

Carden is a brand name for a synthetic medicinal entity whose sole active compound is the generic substance Atenolol. It is supplied as a prescription-only medicine (Rx), manufactured for oral administration in the form of an oral tablet. The drug's primary purpose is to modulate the cardiovascular system, reducing stress and promoting circulatory stability.


Carden: A Cardioselective Beta-Blocker

Carden is classified pharmacologically as a beta-adrenergic blocking agent, specifically a cardioselective beta-blocker. This classification means the drug primarily targets beta1-receptors in the heart, inducing a controlled slowing of the heart rate (negative chronotropic effect) and a reduction in the force of heart contractions. This mechanism is generally utilized for patients requiring consistent management of conditions that place an excessive workload on the heart, such as high blood pressure. Pharmacological studies demonstrate the ability of Atenolol to attenuate the heart rate response to physical or mental stress. Therefore, the medicine serves as a tool for achieving long-term circulatory stability.


Key Differentiating Properties of Atenolol

The active ingredient, Atenolol, is distinguished from many older beta-blockers by its hydrophilic (water-soluble) nature. This chemical characteristic means Atenolol poorly penetrates the central nervous system. Furthermore, unlike some analogues that are primarily metabolized by the liver, Atenolol is eliminated mainly through renal excretion, a fact recognized for influencing its dosing requirements, especially in patients with impaired kidney function.

Regulatory References

  1. U.S. National Library of Medicine
  2. DailyMed, Atenolol Label

What side effects are possible with Carden?

Carden's safety profile, defined by official regulatory bodies, structures possible adverse reactions into categories based on the physiological system affected and the reported incidence in clinical trials.


Adverse Reactions and Frequencies

Adverse reactions are classified by frequency, with Common (1 to 10 users in 100) effects typically involving the cardiovascular and nervous systems, such as fatigue, bradycardia (slow heart rate), coldness of the extremities, and gastrointestinal disturbances. Uncommon effects (0.1% to 1%) include sleep disturbances and nightmares. Reactions classified as Rare (0.01% to 0.1%) include mood changes, dizziness, headache, skin rash, impotence, and the precipitation of heart block.


Safety Restrictions and Special Populations

Official labeling mandates several safety restrictions. The medicine is strictly contraindicated in patients with pre-existing conditions such as sinus bradycardia, heart block greater than first degree, cardiogenic shock, and overt cardiac failure.

Population-Specific Safety Notes:

  • Renal Impairment: Because the medicine is eliminated primarily by the kidneys, its clearance is reduced in patients with impaired renal function, necessitating caution.
  • Diabetes: The drug may mask certain symptoms of hypoglycemia (low blood sugar), specifically a rapid heartbeat.
  • Abrupt Discontinuation: A serious warning exists regarding the potential for adverse cardiovascular events, including worsening angina or myocardial infarction, if treatment is suddenly withdrawn.

This framework of frequency-classified effects and defined contraindications ensures the acknowledged potential for serious events is clearly communicated as the basis for safe use, particularly in vulnerable patients.

Overdose and Emergency Response

Overdose Manifestations

Carden overdose is a severe event documented by regulatory authorities as potentially life-threatening. Manifestations center on profound cardiodepression, including severe bradycardia (slow heartbeat), sustained hypotension (low blood pressure), and the onset of acute heart failure. Neurological manifestations are also officially described, ranging from confusion, drowsiness, and weakness to severe outcomes like seizures and coma. Ingestion of excessive amounts can result in shock and, ultimately, death if not managed aggressively.

Mandated Emergency Actions

Emergency medical help is required immediately upon suspicion of an overdose. Regulators mandate calling emergency services if the victim has collapsed, is experiencing trouble breathing, or cannot be awakened. Treatment is strictly symptomatic and supportive as no specific antidote is known. Procedures documented in official management plans include the administration of activated charcoal and the provision of intravenous fluids and specialized support to stabilize the cardiovascular system. Due to the risk of low blood sugar, overdose in pediatric patients requires careful monitoring for hypoglycemia. Hospital observation, including ECG and vital signs monitoring, is necessary.

Therapeutic Uses of Carden

What Carden treats: main uses and benefits

Carden, the brand name for nicardipine, is a medication that may be part of symptomatic management for conditions characterized by periods of heightened symptoms related to the cardiovascular system. The medication is considered relevant for managing two main therapeutic areas, namely high blood pressure (hypertension) and angina (chest pain).


In clinical settings that involve acute or unstable symptom patterns, the medication is commonly used to help with these conditions involving episodic or fluctuating manifestations. For patients experiencing symptoms related to heightened physiological activity, treatment assists with maintaining functional stability. For those with stable angina, a condition where symptoms may intensify temporarily and create symptoms related to physical discomfort, the supportive action may assist with easing the symptoms that become more disruptive during flare-ups. This provides support that helps ease the overall symptom burden and helps patients cope more steadily.

“This supportive action may assist with easing the symptoms that become more disruptive during flare-ups.”

Quick Fact: Relief for Heightened Physiological Activity

The medicine is applied across domains where additional symptomatic support is needed to help manage these vascular and cardiac states, which supports general well-being during symptomatic phases.

Regulatory References

  1. NIH MedlinePlus overview of Nicardipine

Eligibility and Restrictions for Use

Carden (Atenolol) eligibility is strictly defined by regulatory documents, categorizing who may and who must not use the medicine.

Populations with Absolute Non-Eligibility (Contraindicated)

Use is prohibited in patients with:

  • Cardiogenic shock or uncontrolled heart failure.
  • Severe bradycardia or heart block greater than first degree.
  • Bronchial asthma or severe Chronic Obstructive Pulmonary Disease (COPD).
  • Known hypersensitivity to Atenolol.

Age- and Condition-Based Restrictions

The following groups require strict caution or are not recommended:

  • Pediatric Population: Use is not recommended in children and adolescents under 18 years; safety and efficacy are not established.
  • Severe Renal Impairment: Requires mandatory dosage adjustment due to the drug's elimination route.
  • Pregnancy and Lactation: Use is restricted and requires caution due to documented risks to the fetus and neonate.
  • Older Adults: Requires cautious dose selection due to a higher frequency of decreased renal function.
  • Diabetes and Thyrotoxicosis: Caution is required as the medicine may mask symptoms of hypoglycemia or hyperthyroidism.

What should I know about interactions with other medicines?

Carden's official regulatory documentation structures its interaction profile primarily around effects on cardiac function and constraints on absorption.

Documented Interaction Classifications

Category Officially Documented Constraint
Formal Contraindication Co-administration via the intravenous route with Verapamil or Diltiazem is explicitly contraindicated due to the severe risk of additive negative effects on heart rate and contractility (pharmacodynamic synergism).
Cardiovascular Risk The combination with Clonidine requires a specific procedural constraint: Carden must be discontinued several days prior to the cessation of Clonidine to prevent the official risk of severe rebound hypertension.
Additive Pharmacodynamic Effects Co-administration with other anti-arrhythmics or cardiac glycosides (e.g., Digoxin) may potentiate effects on conduction time, increasing the risk of bradycardia.

Absorption and Efficacy Constraints

Category Officially Documented Constraint
Timing Requirement Antacids containing Aluminum Hydroxide may inhibit gastrointestinal absorption, resulting in reduced Carden plasma exposure. To mitigate this effect, administration must be separated by at least 2 hours.
Antagonism of Effect Concomitant use with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) such as Indomethacin is documented to result in an antagonism that may reduce Carden's intended antihypertensive efficacy.
Accumulation Risk Due to Carden's reliance on the kidneys for elimination, its clearance is substantially reduced in the presence of impaired renal function. This condition is noted in the interaction profile as it leads to potential drug accumulation when co-administered.

Mechanism of Action

Selective Receptor Binding

Carden is a selective estrogen receptor modulator (SERM). Its action is mediated by binding to the estrogen receptor (ER). This binding alters the receptor's conformation, resulting in tissue-specific activity: Carden acts as an agonist in bone tissue and an antagonist in mammary and uterine tissue.

Intracellular Signaling Cascade

In bone, this conformational change initiates a specific intracellular signaling cascade. It alters the transcriptional activity of estrogen-responsive genes within bone cells. This molecular modification leads to the direct modulation of osteoclast differentiation and function.

Modulating Bone Cell Balance

This selective effect modulates the physiological balance between osteoblast (bone-forming) and osteoclast (bone-resorbing) activity. The process alters the expression of key cytokines involved in bone resorption at a system level.

Dosage and Administration Information

Administration Routes and Forms

Carden (Atenolol) is supplied for two primary administration methods: as an oral tablet for long-term maintenance and as an intravenous (IV) injection for initial use in acute clinical settings. Available tablet strengths are typically 25 mg, 50 mg, and 100 mg.

Standard Dosing Principles

Administration is usually based on a once-daily schedule, though the total daily dose may be divided into two smaller doses for certain indications.

Indication (High-Level) Starting Dose Maintenance Dose Range
Hypertension 25 mg to 50 mg once daily 50 mg to 100 mg once daily
Angina Pectoris 50 mg once daily 50 mg to 100 mg once daily

For oral intake, the tablets must be swallowed whole with liquid, and it is generally advised to take the medicine before meals. If a dose is missed, the next dose should be taken at the scheduled time, and a double dose must not be taken to compensate.

Population-Specific Usage and Tapering

Dosage requires adjustment in the presence of impaired kidney function due to the drug's primary renal elimination. For patients with low creatinine clearance, the maximum daily dose is significantly reduced. Similarly, a lower initial dose of 25 mg once daily may be appropriate for older adults.

Treatment must not be discontinued abruptly. Instead, the dose must be gradually reduced over a period of 7 to 14 days to follow the protocol for cessation.

Recent Clinical Evidence

Research evidence / Overview of studies for Carden

Evidence for Use in High Blood Pressure (Hypertension)

Research into Carden (Atenolol) for managing high blood pressure consists primarily of large-scale, randomized controlled trials (RCTs) and subsequent systematic reviews or meta-analyses. These trials were typically conducted on adult populations and were designed to compare the medicine against placebo or against other major medication classes of anti-hypertensive drugs.

The outcomes monitored by researchers included measurements of systolic and diastolic blood pressure levels and long-term cardiovascular events. Findings describe patterns observed in the studies that showed the medicine was associated with an attenuation of blood pressure levels. The research provides context, but evidence remains limited for comparative long-term outcomes, such as stroke and all-cause mortality, particularly against some contemporary treatments.

Evidence for Use in Chest Pain (Chronic Stable Angina)

Research for chronic stable angina is based mainly on short-term, controlled Randomized Controlled Trials (RCTs). These studies focused on adult patients who experience conditions involving periods of heightened symptoms related to coronary artery disease.

Researchers primarily examined functional outcomes and patient-reported experiences, including measurements of exercise tolerance and the heart’s workload (rate-pressure product). Findings describe patterns observed in the studies that show a consistent change in these measured outcomes. However, follow-up durations were limited, and there is limited information for long-term outcomes regarding the overall risk of major cardiovascular events specifically in the stable angina population.

Evidence in Special Populations

Research has explored the use of Atenolol in certain groups beyond the general adult population. Specific studies research examined its use in older adults with hypertension and in patients with co-existing conditions, such as impaired kidney function. Furthermore, retrospective studies was evaluated in certain pediatric populations for managing specific cardiac rhythm issues. However, data for certain groups remain insufficient due to smaller sample sizes, and the evidence quality for specialized uses in children may be limited.

Key Studies & References

  1. Label: ATENOLOL tablet - DailyMed (Official Regulatory Monograph)
  2. Should beta blockers remain first choice in the treatment of primary hypertension: a meta-analysis
  3. Atenolol in hypertension: is it a wise choice? (Systematic Review)

Frequently Asked Questions (FAQ)

Common questions about Carden (FAQ)


Q: How long does the effect of one Carden tablet last in the body?

According to official product information, Carden is designed for once-daily dosing because its chemical elimination half-life is around 6 to 7 hours. The beta-blocking and antihypertensive effects are generally noted to persist for at least 24 hours.


Q: Does Carden need to be taken with a meal or on an empty stomach?

Regulatory documents suggest that taking Carden before meals may be beneficial. However, official product information also indicates that the overall effects on the heart are similar whether the medicine is taken while fasting or after eating. It is important to follow the specific instructions provided by the healthcare prescriber.


Q: What are the warnings regarding Carden use in patients with diabetes?

Official warnings state that Carden may make blood sugar control more difficult if you take diabetic medicines. Additionally, it can mask the symptom of a rapid heartbeat that usually signals low blood sugar (hypoglycemia). This information highlights the need for close monitoring under medical supervision.


Q: What should a user do if they miss one dose of Carden?

Official guidance instructs the user to take the next dose at the regularly scheduled time and explicitly states that a double dose must not be taken to compensate for the missed dose. For questions about specific timing or individual guidance, consult a healthcare professional.


Q: Is dizziness when rising up from sitting or lying down a reported side effect?

Dizziness or lightheadedness, including when changing position (postural hypotension), is a reported side effect of Carden. This reported effect is associated with the medicine’s action to lower blood pressure.


Q: How quickly can Carden begin to affect blood pressure after the first dose?

Following a single oral dose, beta-blocking effects are apparent within 1 hour and maximal within 2 to 4 hours. A measurable reduction in blood pressure is often observed within three hours of administration.


Q: What should a patient look for to know if Carden is working for them?

The effectiveness of Carden is generally measured by its intended effects on the cardiovascular system, which is assessed through monitoring. For high blood pressure, the intended effect is a measurable lowering of blood pressure readings. If used for angina, the intended effect is a reduction in chest pain episodes.


Q: What are the considerations for using Carden in older adult populations?

Regulatory documents indicate that a lower initial dose, such as 25 mg once daily, may be appropriate for older adults. This is because older populations have a higher frequency of decreased renal function, which affects the body's elimination of the medicine and is why a cautious approach to dose selection is used.


Q: Does Carden affect mood, such as causing depression or anxiety?

Carden has reported side effects involving the nervous system and mood. Mood changes, which include depression, are listed as a rare side effect in official documents. Sleep disturbances and nightmares are also reported, generally classified as uncommon effects.


Q: Can Carden interact with other prescription medicines used for heart conditions (like calcium channel blockers)?

Official documentation describes interactions with other heart medicines. Using it with certain anti-arrhythmics or cardiac glycosides (like Digoxin) may increase the risk of a slow heart rate. Furthermore, co-administration via the intravenous route with medicines like Verapamil or Diltiazem is strictly prohibited.


Q: Is Carden used to treat conditions other than hypertension, angina, and arrhythmia?

Yes. Beyond treating high blood pressure, chest pain (angina), and certain irregular heart rhythms, the active ingredient in Carden is also approved for use in the management of stable patients following a definite or suspected acute heart attack (myocardial infarction).


Q: Is Carden generally considered non-habit-forming?

Carden is not categorized as a controlled substance by regulatory bodies, and it is not generally considered to be a habit-forming drug. However, regulatory documents emphasize that treatment should not be discontinued suddenly, requiring a gradual dose reduction under medical supervision.


Q: What are the most common side effects listed for Carden?

The most common reported side effects (Common or Very Common) include feelings of fatigue or tiredness, a slow heart rate (bradycardia), and coldness or numbness in the hands and feet. Gastrointestinal disturbances, such as diarrhea or nausea, are also frequently reported in official product information.


Q: Can Carden cause extreme tiredness or fatigue?

Yes, fatigue and tiredness are among the most commonly reported side effects of Carden. Official product information classifies these effects as 'Common,' with reports from studies indicating they are very frequent in some patient groups.


Q: What is the official stance on consuming alcohol while using Carden?

Official information indicates that taking Carden together with alcohol may result in additive effects that further lower blood pressure. This combination can increase the risk of related side effects such as excessive dizziness or feeling lightheaded.


Q: Does Carden have known interactions with over-the-counter pain relievers (NSAIDs)?

Yes. Regulatory documents note that the combined use of Carden with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), such as Indomethacin or Ibuprofen, may lead to a reduction in Carden's intended blood pressure-lowering effect.


Q: Does Carden have a risk of drug-induced sexual dysfunction?

Sexual dysfunction, specifically including impotence (the inability to have or maintain an erection), is a reported side effect of Carden. This effect is generally classified as Rare in official adverse reaction summaries.


Q: Does Carden have an impact on blood sugar levels?

Regulatory documentation states that Carden may interfere with the body's normal blood glucose control. Official information suggests it may increase the risk, severity, and/or duration of low blood sugar (hypoglycemia), especially in individuals taking other medications for diabetes.


Q: Is Carden known to cause issues with sleep (insomnia or vivid dreams)?

Official adverse reaction reports list sleep disturbances and nightmares as uncommon side effects. Insomnia (difficulty falling or staying asleep) and vivid or unusual dreams have also been reported by users of Carden.


Q: Can the effectiveness of Carden decrease over many years of continuous use?

The official product information does not indicate that the drug's fundamental activity is altered by long-term use. However, the need for regular monitoring of blood pressure and heart rate is emphasized, suggesting that treatment effectiveness should be periodically reviewed by a healthcare professional.


Q: Does Carden have any known interactions with grapefruit or grapefruit juice?

Carden (Atenolol) is generally not listed as interacting with grapefruit juice in the same way as some other heart medications. However, official drug information advises general caution, as consuming products that affect blood pressure may increase the risk of related side effects.


Q: Is there a link between Carden and hair loss?

Temporary hair loss is a side effect that has been reported in association with Carden use. Regulatory documents often classify this particular effect as Rare or an effect whose incidence (how often it occurs) is not clearly determined in clinical trials.


Q: How does Carden compare to other common beta-blockers in terms of action or classification?

Carden is officially classified as a cardioselective beta-blocker, meaning it primarily affects beta1-receptors in the heart. It is also distinguished as a hydrophilic (water-soluble) drug, which means it tends to enter the brain and central nervous system less readily than some older, non-selective beta-blockers.


Q: Why is regular blood pressure or heart rate monitoring important while taking Carden?

Official labeling indicates that regular monitoring of heart rate and blood pressure is necessary for safety and effectiveness. Monitoring is indicated to ensure the treatment is functioning as expected to achieve the desired blood pressure, detect severe bradycardia (slow heart rate), and help prevent symptomatic low blood pressure.


Q: Is a rash or persistent itching a reported side effect of Carden?

Skin rash is listed as a Rare side effect in the official safety profile. Itching (pruritus) or hives is also reported in association with the medicine. These symptoms are noted, and a rash is listed as a Rare side effect.

How should Carden be stored and disposed of?

How to Store and Dispose of Carden (Atenolol)

The official labeling for Carden (atenolol) defines strict storage and handling requirements to maintain product stability and ensure safe disposal.

Required Storage Conditions

Condition Requirement
Temperature Store at Controlled Room Temperature (20 C to 25 C), and do not store above 25 C.
Protection The product must be kept from freezing, protected from light, and stored away from excess heat and moisture.
Packaging The medicine must be kept in a tightly closed, light-resistant container and stored in the original package.

Disposal and Safety

Carden must be kept out of the sight and reach of children. Unused or expired tablets should not be kept and must not be disposed of via household trash or wastewater. Patients must ask a healthcare professional or pharmacist for instructions on proper disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Carden found in:

A-Z Index: